BioSpace News Archive

Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company’s Chairman of the Board, Prof. Dr. Slawomir Majewski, will immediately assume the role of Interim CEO.

RETINA-AI Health, Inc. today announced positive results from the pivotal study of the RETINA-AI Galaxy™, a multi-device compatible autonomous diabetic retinopathy screening device intended for use in primary care settings.

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has initiated SURTORI-01, a Phase III study to evaluate the efficacy and safety of surufatinib (SULANDA® in China) in combination with toripalimab compared with FOLFIRI to treat patients with advanced neuroendocrine carcinoma (“NEC”) who have progression of disease or intolerable toxicity after previous first-line chemotherapy.

Telix Pharmaceuticals Limited has welcomed the Society of Nuclear Medicine and Molecular Imaging updated Appropriate Use Criteria for prostate specific membrane antigen positron emission tomography imaging.